Similar articles

• Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.

  Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, Korioth-Schmitz B, Yu F, Rohne D, Martin KL, Miura A, Kong WP, Yang ZY, Gelman RS, Golubeva OG, Montefiori DC, Mascola JR, Nabel GJ. Letvin NL, et al. J Virol. 2004 Jul;78(14):7490-7. doi: 10.1128/JVI.78.14.7490-7497.2004. J Virol. 2004. PMID: 15220422 Free PMC article.
• Human trials of AIDS vaccines: current status and future directions.

  Koff WC, Fauci AS. Koff WC, et al. AIDS. 1989;3 Suppl 1:S125-9. AIDS. 1989. PMID: 2558684 Review. No abstract available.
• Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

  [No authors listed] [No authors listed] Dis Markers. 1991 Jan-Feb;9(1):51. Dis Markers. 1991. PMID: 1742945 No abstract available.
• Characterization of a vaccinia-derived recombinant HIV-1 gp160 candidate vaccine and its immunogenicity in chimpanzees.

  Barrett N, Eder G, Dorner F. Barrett N, et al. Biotechnol Ther. 1991;2(1-2):91-106. Biotechnol Ther. 1991. PMID: 1845126
• How antibodies block HIV infection: paths to an AIDS vaccine.

  Putney S. Putney S. Trends Biochem Sci. 1992 May;17(5):191-6. doi: 10.1016/0968-0004(92)90265-b. Trends Biochem Sci. 1992. PMID: 1350693 Review.